Skip to content
Review

Abstract 5159: Comparative Effectiveness and Safety of Myval versus Evolut Transcatheter Heart Valves in Severe Aortic Stenosis: A Systematic Review and Meta-Analysis

Nov 2026 · Circulation · 0 citations

Abstract

Introduction/Background: The Myval balloon-expandable transcatheter heart valve (THV) has emerged as an alternative to established platforms; however, comparative evidence with the Evolut self-expanding THV remains limited, particularly regarding procedural performance and conduction outcomes. Research Questions/Hypothesis: We evaluated comparative clinical and procedural outcomes between Myval and Evolut THVs in patients undergoing transcatheter aortic valve implantation (TAVI). Methods/Approach: A systematic search of PubMed, EMBASE, Scopus, and the Cochrane Library was conducted for studies published through March 2026. Eligible studies were observational comparative cohorts directly comparing Myval and Evolut THVs. Quality was appraised using the Newcastle-Ottawa Scale and certainty of evidence using the GRADE approach. Primary outcomes included all-cause mortality, permanent pacemaker implantation (PPI), and transvalvular aortic regurgitation. Secondary outcomes included technical success and vascular complications. Pooled risk ratios (RRs) with 95% confidence intervals (CIs) were calculated using a random-effects model. Heterogeneity was assessed using I 2 statistics, and publication bias was evaluated using funnel plots. Results/Data: Six observational studies (n=1332) were included. Myval was associated with a significantly lower PPI risk (RR 0.56, 95% CI 0.37-0.84; p=0.005; I 2 =0%) and comparable 30-day mortality (RR 0.83, 95% CI 0.31-2.23; p=0.72; I 2 =0%). No significant difference was observed in transvalvular aortic regurgitation (RR 0.25, 95% CI 0.03-1.97; p=0.19; I 2 =45%); however, sensitivity analysis excluding one heterogeneity-driving study demonstrated a significant reduction favoring Myval (RR 0.10, 95% CI 0.02-0.56; p=0.008; I 2 =0%). Myval demonstrated higher technical success (RR 1.06, 95% CI 1.03-1.10; p<0.001; I 2 =0%) and lower minor vascular complications (RR 0.40, 95% CI 0.18-0.85; p=0.02; I 2 =8%). Stroke (RR 0.79, 95% CI 0.29-2.15; p=0.65; I 2 =0%) and acute kidney injury (RR 0.35, 95% CI 0.07-1.79; p=0.21; I 2 =55%) rates were similar. Conclusion: In patients undergoing TAVI, balloon-expandable THVs were associated with lower PPI risk and higher technical success compared with self-expanding systems. While no significant difference in transvalvular aortic regurgitation was observed, sensitivity analysis suggests improved valve sealing with Myval. These findings support their use as a viable alternative to established self-expanding systems.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.